ARV-T1/DSPC/cholesterol/DMG-PEG2000 = 50:10:38.5:1.5 mol%; reported N/P = 4. Source: Methods, LNP formulation. DMG-PEG2000 uses 2507 for calculated component masses. A lipid:RNA mass ratio is not inferred from N/P.
Component mass calculator
Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.
Component
MW
Molar ratio
Mass (mg)
Mass %
ARV-T1
DSPC
Cholesterol
DMG-PEG2000
Particle properties
Experiment / parameter
Study conditions
Result / interpretation
Apparent pKa
TNS assay on LNPs without encapsulated mRNA; Fig. 2F
6.73; this is a formulation-dependent measurement, not an isolated-molecule pKa.
Hydrodynamic size
Fig. 2 and Discussion
Approximately 80 nm for ARV-T1 versus 90 nm for the SM-102 comparator.
Encapsulation
Fig. 2
Both formulations exceeded 90% RNA encapsulation.
Dispersity and surface potential
Fig. 2
ARV-T1 showed lower PDI and greater absolute zeta potential than the comparator; the text describes magnitudes of approximately 10 versus 5 mV.
Cellular expression and viability
Experiment / parameter
Study conditions
Result / interpretation
Protein expression
HEK293T cell experiments; Fig. 3
ARV-T1 LNPs produced higher antigen expression than the matched SM-102 formulation. No fold change is inferred from chart heights.
Cell viability
HEK293T and Huh7; 48 h; Fig. 7A
No significant reduction was reported across most tested concentrations; a high-concentration effect was observed in Huh7 at 125 µM.
Intramuscular reporter kinetics
Experiment / parameter
Study conditions
Result / interpretation
Study conditions
BALB/c mice, n = 6; 1 µg luciferase mRNA IM
Luminescence assessed at 6, 24, 48 and 72 h (Fig. 5).
ARV-T1 expression
Peak at 24 h
Approximately 50% of peak signal remained at 72 h.
SM-102 comparator
Peak at 6 h
Signal declined rapidly and was barely detectable at 72 h in this experiment.
Antibody responses
Experiment / parameter
Study conditions
Result / interpretation
Prime/boost study
Mouse immunization on days 1 and 21; readouts days 14 and 35; Fig. 6
The authors report >10-fold higher potency for antigen-binding and neutralizing-antibody responses compared with the study SM-102 formulation.
Dose-response interpretation
Low-dose vaccine comparisons
Antibody potency is not a measure of tenfold higher transfection in every tissue, and is not a human vaccine efficacy estimate.
Storage and in vivo tolerability
Experiment / parameter
Study conditions
Result / interpretation
Frozen storage
12 weeks at −20°C versus −80°C; Fig. 4C
Cellular protein expression was similar, although PDI increased at −20°C.
Refrigerated storage
12 weeks at 4°C; Fig. 4C
Approximately 50% fewer antigen-positive cells and 66% lower median fluorescence than the frozen groups.
Repeated IM administration
Two doses separated by three weeks; Fig. 7
Blood chemistry one day after the last dose and tissue histology two weeks later showed no reported abnormal changes; body weight was not significantly altered.
Scope
Study formulation and observation windows
The study does not establish human, chronic or unrestricted-dose safety. Storage findings do not define the isolated reagent shelf life.